Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Spring;13(1):57-78.
doi: 10.1111/j.1527-3458.2007.00005.x.

Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug

Tim De Smedt  1 , Robrecht Raedt, Kristl Vonck, Paul Boon
Affiliations
Review

Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug

Tim De Smedt et al. CNS Drug Rev. 2007 Spring.

Abstract

The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add-on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.

PubMed Disclaimer

References

    1. Alsaadi TM, Thieman C (2003) Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 12:154‐156. - PubMed
    1. Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S (2005) Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1‐year follow‐up study. Seizure 14:139‐142. - PubMed
    1. Arroyo S, Crawford P (2003) Safety profile of levetiracetam. Epileptic Disord 5:57‐63. - PubMed
    1. Arroyo S, Chadwick DW, French J, Mattson R, Perucca E (2004) Epilepsies and convulsive disorders, Chapter 16, in: The IUPHAR Compendium of Basic Principles For Pharmacological Research in Humans (Du Souich P, Orme M, Erill S. eds.) p. 165‐182, International Union of Basic and Clinical Pharmacology, Irvine , California .
    1. Bauer J, Ben‐Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn‐Nolst TDG (2006) Levetiracetam: A long‐term follow‐up study of efficacy and safety. Acta Neurol Scand 114:169‐176. - PubMed

Publication types